On World Cancer Day 2026, oncologists spoke about the early signs of prostate cancer, which are often mistaken for ...

A Registrational Phase 2 clinical trial has been initiated in Japan for patients with PSMA-positive metastatic castration-resistant prostate ...

“Oxybutynin demonstrated clear and clinically meaningful improvements in both hot flash frequency and quality of life for men undergoing hormone therapy for prostate cancer,” said lead researcher Dr.

Researchers at VCU Massey Comprehensive Cancer Center and the VCU Institute of Molecular Medicine (VIMM) were recently awarded a $1.8 million, 3-year grant from the United States Department of Defense ...

Akeega, an oral dual mechanism therapy pairing niraparib with abiraterone, has won a positive committee opinion in Europe for ...

Decades ago, doctors created a test to determine which breast cancer patients should receive hormone therapy. Now, ...

A national clinical trial led by the Alliance for Clinical Trials in Oncology has found that oxybutynin, a drug often used to ...

Prostate cancer (PCa) is one of the most common malignant tumors among men worldwide. Following androgen deprivation therapy ...

As we gear up to observe World Cancer Day 2026 under the theme 'United by Unique', let's take a look at the stages of ...

Men with prostate cancer who get hormone therapy experience hot flashes, where they experience intense and sudden heat and ...

Thousands of men in England living with advanced prostate cancer are poised to benefit from a new life-extending drug, ...